• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Management of dermatologic adverse events with apalutamide in prostate cancer

Video

“The majority of patients were able to stay on the dose of the apalutamide,” says Mario E. Lacouture, MD.

In this video, Mario E. Lacouture, MD, discusses the background, findings, and takeaways of the Journal of Urology study, “Dermatologic adverse events in prostate cancer patients treated with androgen receptor inhibitor apalutamide.” Lacouture is a dermatologist at Memorial Sloan Kettering Cancer Center in New York, New York.

Related Videos
A panel of 4 experts on prostate cancer
A panel of experts on prostate cancer
A panel of 4 experts on prostate cancer
A panel of 4 experts on prostate cancer
A panel of 4 experts on prostate cancer
A panel of 4 experts on prostate cancer
A panel of 4 experts on prostate cancer
A panel of 4 experts on prostate cancer
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.